Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 28 peer-reviewed journal articles Updated
Oncology

Life After Treatment: Monitoring, Side Effects, and Survivorship

At a Glance

After adrenal cancer treatment, long-term follow-up is important because recurrence can occur years later. Care may include tailored scans and blood tests, steroid replacement and emergency planning, mitotane interaction monitoring, emotional support, and genetic testing for relatives.

Treatment for adrenal cancer is often just the first step. Because these diseases can recur, long-term monitoring is essential for your safety and peace of mind [1][2].

Monitoring for Recurrence: Your Surveillance Plan

The goal of surveillance is to catch any sign of the cancer returning as early as possible. For ACC, recurrence often happens in the area where the tumor was removed (the “tumor bed”), the lungs, or the liver [1][3].

Important: There is no single universal follow-up plan. Your schedule will be tailored to your specific tumor stage, margins, hormone phenotype, genetic status, and kidney function.

Example Surveillance for ACC

A common framework for high-risk ACC includes [1][4]:

  • Years 1–2: Every 3 to 6 months. This usually includes cross-sectional imaging (CT or MRI) of the chest, abdomen, and pelvis, along with relevant blood tests.
  • Years 3–5: Every 6 months, provided no new issues have been found.
  • After 5 Years: Continued long-term monitoring, as late recurrences can happen, with annual visits for at least 10 years or more [5][6].

Example Surveillance for PPGL

Monitoring for PPGL varies substantially based on whether the disease is sporadic or hereditary, the primary location, and prior metastasis. It typically involves regular blood tests for metanephrines and periodic imaging (like a “rapid” whole-body MRI) every two years, which is often lifelong for those with genetic mutations (like SDHB) [7][8][9].

Living with Adrenal Insufficiency

If you had both adrenal glands removed, you will have permanent primary adrenal insufficiency. If you are taking mitotane, your adrenal function is suppressed and you also require steroid replacement [10].

  • Steroid Replacement: You will take medications—usually hydrocortisone and sometimes fludrocortisone—to replace what your body is missing [11].
  • Sick Day Rules: When your body is under physical stress (fever, infection, or surgery), it needs extra cortisol. You must follow your clinician’s specific plan for “stress dosing” to prevent a life-threatening adrenal crisis [11][12].
  • Emergency Kit: Always carry a medical-alert ID and an emergency injection kit of hydrocortisone for use if you cannot keep pills down [13][14].
  • Adrenal Recovery: If you stop mitotane, your adrenal glands might recover, but it is slow and variable (averaging over 2 years in some cohorts) [15]. You must stay on your steroids until your doctor proves your body is making its own cortisol again [16][17].

Managing Mitotane Side Effects and Interactions

Mitotane remains in your body for months or even years after you stop taking it, and its side effects can be chronic and require active management [16][18].

  • Drug Interactions: Mitotane is a strong “enzyme inducer.” It rapidly speeds up how your body processes other drugs, making medications like blood thinners (anticoagulants) and sedatives less effective. It also severely reduces the reliability of hormonal contraceptives. You must use reliable non-hormonal contraception and check every new prescription with your oncology team [19].
  • Neurological and Endocrine Effects: Mitotane can cause “brain fog,” dizziness, trouble concentrating, hypothyroidism, and elevated cholesterol [20][21]. Your team will regularly monitor your thyroid, liver, and lipid panels, and these can be managed with standard medications [22][23].

“Scanxiety” and Genetic Cascade Testing

The psychological weight of frequent scans—often called scanxiety—is a significant challenge. Quality of life topics (sleep, fatigue, mental health) are just as important to discuss with your team as your imaging results [24].

If your cancer is linked to a genetic mutation, it is vital to discuss cascade testing with your family [25][26]. Finding a mutation in a relative does not guarantee they will get cancer, but it raises their risk. Identifying these variants allows them to enter specialized, gene-specific screening programs that can detect tumors when they are small and highly curable [27][28].

Your survivorship care is a partnership with your medical team. By staying diligent with your monitoring, understanding your medications, and preparing for emergencies, you take an active role in your long-term health.

Common questions in this guide

How often should I have follow-up scans after adrenal cancer treatment?
There is no single schedule for everyone. For higher-risk adrenocortical carcinoma, follow-up commonly includes CT or MRI of the chest, abdomen, and pelvis every 3 to 6 months during the first 2 years, every 6 months through years 3 to 5, and then ongoing annual visits because recurrence can occur late. Your schedule should reflect tumor stage, surgical margins, hormone pattern, genetics, and kidney function.
What follow-up tests are used for pheochromocytoma or paraganglioma?
Monitoring depends on whether the tumor was sporadic or inherited, where it started, and whether it had spread. It often includes blood tests for metanephrines and periodic imaging, such as whole-body MRI every two years; people with inherited mutations such as SDHB may need lifelong surveillance.
Will I need steroid replacement after adrenal cancer surgery or mitotane?
If both adrenal glands were removed, permanent primary adrenal insufficiency is expected. Mitotane can also suppress adrenal function, so hydrocortisone and sometimes fludrocortisone may be needed. Do not stop replacement until testing confirms that your body is producing enough cortisol.
What should I do if I become sick while taking steroid replacement?
Fever, infection, or surgery can increase your body's need for cortisol, so follow the written stress-dose or sick-day plan from your clinician. Carry a medical-alert ID and an emergency hydrocortisone injection kit, and use the injection as instructed if you cannot keep your pills down. Seek urgent medical help for possible adrenal crisis.
What mitotane side effects and drug interactions should I watch for?
Mitotane can remain in the body for months or years and can cause brain fog, dizziness, trouble concentrating, thyroid problems, or high cholesterol. It can make some medicines, including blood thinners and sedatives, less effective and can greatly reduce the reliability of hormonal contraceptives. Ask your oncology team to review every new medicine and use reliable non-hormonal contraception as advised.
Should my family be tested if my adrenal cancer is linked to a genetic mutation?
Ask a genetics professional whether cascade testing is appropriate for blood relatives. A mutation can raise a relative's risk without guaranteeing that cancer will develop. If a relative carries the variant, gene-specific screening can help find tumors earlier, and the care team can discuss when screening should begin.
How can I manage anxiety about follow-up scans?
Scan-related anxiety, sometimes called scanxiety, is a real survivorship concern. Tell your care team about sleep problems, fatigue, or mental health distress; planning a routine, bringing a support person, and asking about counseling or other support may help. Emotional well-being deserves attention alongside scan results.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my individualized surveillance schedule for the next 2–5 years based on my tumor's stage, margins, and genetics?
  2. 2.How will we monitor my adrenal function, and how often will we reassess if my adrenal glands are recovering if I have stopped mitotane?
  3. 3.Given my mitotane dose, what symptoms (like memory changes or dizziness) should I report immediately as potential signs of neurotoxicity?
  4. 4.If I am on steroid replacement, do I have a written 'sick day rule' plan and an emergency injection kit?
  5. 5.Does my genetic test result mean my relatives need specific screening, and at what age should that begin?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (28)
  1. 1

    European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors

    Fassnacht M, Dekkers OM, Else T, et al.

    European journal of endocrinology 2018; (179(4)):G1-G46 doi:10.1530/EJE-18-0608.

    PMID: 30299884
  2. 2

    American Association of Clinical Endocrinology Disease State Clinical Review on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach.

    Kiseljak-Vassiliades K, Bancos I, Hamrahian A, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2020; (26(11)):1366-1383 doi:10.4158/DSCR-2020-0567.

    PMID: 33875173
  3. 3

    [Adrenal imaging: anatomy and pathology (literature review)].

    Korb TA, Chernina VY, Blokhin IA, et al.

    Problemy endokrinologii 2021; (67(3)):26-36 doi:10.14341/probl12752.

    PMID: 34297499
  4. 4

    The Overall Survival and Progression-Free Survival in Patients with Advanced Adrenocortical Cancer Is Increased after the Multidisciplinary Team Evaluation.

    Tizianel I, Caccese M, Torresan F, et al.

    Cancers 2022; (14(16)) doi:10.3390/cancers14163904.

    PMID: 36010898
  5. 5

    Past, Present and Future of Epigenetics in Adrenocortical Carcinoma.

    Ettaieb M, Kerkhofs T, van Engeland M, Haak H

    Cancers 2020; (12(5)) doi:10.3390/cancers12051218.

    PMID: 32414074
  6. 6

    Report of a rare case of childhood adrenocortical carcinoma and literature review.

    Wu Z, Qiu L, Zhang M, Chen G

    Urology case reports 2025; (61()):103113 doi:10.1016/j.eucr.2025.103113.

    PMID: 40677937
  7. 7

    Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma.

    Muth A, Crona J, Gimm O, et al.

    Journal of internal medicine 2019; (285(2)):187-204 doi:10.1111/joim.12869.

    PMID: 30536464
  8. 8

    Radiological Surveillance Screening in Asymptomatic Succinate Dehydrogenase Mutation Carriers.

    Tufton N, Sahdev A, Akker SA

    Journal of the Endocrine Society 2017; (1(7)):897-907 doi:10.1210/js.2017-00230.

    PMID: 29264540
  9. 9

    European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma.

    Plouin PF, Amar L, Dekkers OM, et al.

    European journal of endocrinology 2016; (174(5)):G1-G10 doi:10.1530/EJE-16-0033.

    PMID: 27048283
  10. 10

    Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline.

    Bornstein SR, Allolio B, Arlt W, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(2)):364-89 doi:10.1210/jc.2015-1710.

    PMID: 26760044
  11. 11

    Adrenal Insufficiency in Adults: A Review.

    Vaidya A, Findling J, Bancos I

    JAMA 2025; (334(8)):714-725 doi:10.1001/jama.2025.5485.

    PMID: 40522647
  12. 12

    Adrenal crisis: prevention and management in adult patients.

    Dineen R, Thompson CJ, Sherlock M

    Therapeutic advances in endocrinology and metabolism 2019; (10()):2042018819848218 doi:10.1177/2042018819848218.

    PMID: 31223468
  13. 13

    [Emergency card, emergency medication, and information leaflet for the prevention and treatment of adrenal crisis (Addison crisis): an Austrian consensus document].

    Pilz S, Krebs M, Bonfig W, et al.

    Journal fur klinische Endokrinologie und Stoffwechsel 2022; (15(1)):5-27 doi:10.1007/s41969-022-00155-2.

    PMID: 35251520
  14. 14

    Treatment and Prevention of Adrenal Crisis and Family Education

    Çamtosun E, Sangün Ö

    Journal of clinical research in pediatric endocrinology 2025; (17(Suppl 1)):80-92 doi:10.4274/jcrpe.galenos.2024.2024-6-12-S.

    PMID: 39713905
  15. 15

    Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma.

    Reimondo G, Puglisi S, Zaggia B, et al.

    European journal of endocrinology 2017; (177(4)):361-367 doi:10.1530/EJE-17-0452.

    PMID: 28780517
  16. 16

    Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma.

    Poirier J, Gagnon N, Terzolo M, et al.

    Cancers 2020; (12(3)) doi:10.3390/cancers12030639.

    PMID: 32164326
  17. 17

    Glucocorticoid induced adrenal insufficiency.

    Prete A, Bancos I

    BMJ (Clinical research ed.) 2021; (374()):n1380 doi:10.1136/bmj.n1380.

    PMID: 34253540
  18. 18

    Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study.

    Mormando M, Galiè E, Bianchini M, et al.

    Frontiers in oncology 2023; (13()):1222002 doi:10.3389/fonc.2023.1222002.

    PMID: 37645432
  19. 19

    International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: indications, therapy, and management of adverse effects.

    Riedmeier M, Antonini SRR, Brandalise S, et al.

    European journal of endocrinology 2024; (190(4)):G15-G24 doi:10.1093/ejendo/lvae038.

    PMID: 38552173
  20. 20

    Real-world safety profile of mitotane in adrenocortical carcinoma: a retrospective cross-sectional study integrating pharmacovigilance and interpretable machine learning.

    Wang J, Yang Y, Xu K, et al.

    Frontiers in endocrinology 2026; (17()):1862262 doi:10.3389/fendo.2026.1862262.

    PMID: 42558426
  21. 21

    EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity.

    Steenaard RV, Rutjens M, Ettaieb MHT, et al.

    Discover oncology 2022; (13(1)):25 doi:10.1007/s12672-022-00486-1.

    PMID: 35435506
  22. 22

    Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline.

    Poirier J, Godemel S, Mourot A, et al.

    The Journal of clinical endocrinology and metabolism 2023; (108(9)):2336-2342 doi:10.1210/clinem/dgad115.

    PMID: 36856782
  23. 23

    Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients.

    Vikner ME, Krogh J, Daugaard G, Andreassen M

    Clinical endocrinology 2021; (94(2)):141-149 doi:10.1111/cen.14345.

    PMID: 32996176
  24. 24

    Helping young children understand inherited cancer predisposition syndromes using bibliotherapy.

    Schlub GM, Crook A, Barlow-Stewart K, et al.

    Journal of genetic counseling 2021; (30(4)):1119-1132 doi:10.1002/jgc4.1396.

    PMID: 33788335
  25. 25

    Precision Care for Hereditary Urologic Cancers: Genetic Testing, Counseling, Surveillance, and Therapeutic Implications.

    Somoto T, Utsumi T, Ikeda R, et al.

    Current oncology (Toronto, Ont.) 2025; (32(12)) doi:10.3390/curroncol32120698.

    PMID: 41440226
  26. 26

    Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

    Greenberg SE, Skefos CM, Vagher J

    Endocrinology and metabolism clinics of North America 2026; (55(2)):299-315 doi:10.1016/j.ecl.2026.01.002.

    PMID: 42067272
  27. 27

    Surveillance Improves Outcomes for Carriers of SDHB Pathogenic Variants: A Multicenter Study.

    Davidoff DF, Benn DE, Field M, et al.

    The Journal of clinical endocrinology and metabolism 2022; (107(5)):e1907-e1916 doi:10.1210/clinem/dgac019.

    PMID: 35037935
  28. 28

    Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma.

    Buffet A, Ben Aim L, Leboulleux S, et al.

    The Journal of clinical endocrinology and metabolism 2019; (104(4)):1109-1118 doi:10.1210/jc.2018-02411.

    PMID: 30698717

This page is for informational purposes only and does not constitute medical advice. Your oncology and endocrinology teams should tailor surveillance, steroid dosing, emergency planning, and medication decisions to your situation.

Get notified when new evidence is published on Adrenal gland cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.